相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
Zhi Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies
Pauline A. van Schouwenburg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
Christoph Spiess et al.
NATURE BIOTECHNOLOGY (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Pavel Strop et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Christian Klein et al.
MABS (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Resistance to EGFR-Targeted Therapy: A Family Affair
Gregory Vlacich et al.
CANCER CELL (2011)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells
Martin Schlaeth et al.
CANCER SCIENCE (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody
Tomoyuki Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
An Unfolded CH1 Domain Controls the Assembly and Secretion of IgG Antibodies
Matthias J. Feige et al.
MOLECULAR CELL (2009)
Bispecific antibodies for cancer therapy The light at the end of the tunnel?
Patrick Chames et al.
MABS (2009)
Transient expression and purification of chimeric heavy chain antibodies
Jianbing Zhang et al.
PROTEIN EXPRESSION AND PURIFICATION (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines
D. W. Rusnak et al.
CELL PROLIFERATION (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
CW Adams et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Stable antibody expression at therapeutic levels using the 2A peptide
JM Fang et al.
NATURE BIOTECHNOLOGY (2005)
Domain interactions in the Fab fragment:: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability
D Röthlisberger et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
A revival of bispecific antibodies
P Kufer et al.
TRENDS IN BIOTECHNOLOGY (2004)
Protein-protein recognition: Juxtaposition of domain and interface cores in immunoglobulins and other sandwich-like proteins
V Potapov et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector
AL Szymczak et al.
NATURE BIOTECHNOLOGY (2004)
Bispecific human IgG by design
P Carter
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
分享论文
